Clare J. Twist
Academic Appointments
- Associate Professor - Med Center Line, Pediatrics - Hematology & Oncology
Key Documents
Contact Information
-
Clinical Offices
Pediatric Hematology-Oncology 725 Welch Rd MC 5798 Palo Alto, CA 94034 Tel Work (650) 497-8953 Fax (650) 497-8959Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5535Alternate Contact Stephanie Colombo Administrative Assistant Email Tel Work 6507235535Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Oncology (Cancer), Pediatric
- Pediatric Hematology-Oncology
Professional Education
| Internship: | Children's Memorial Hospital IL (1988) |
| Residency: | Children's Memorial Hospital IL (1990) |
| Fellowship: | Children's Hospital Boston MA (1993) |
| Board Certification: | Pediatric Hematology-Oncology, American Board of Pediatrics (1994) |
| Medical Education: | Albany Medical Center NY (1987) |
| Fellowship: | Children's Hospital, Boston/DFCI, Pediatric Hematology & Oncology (1993) |
Scientific Focus
Current Research Interests
My primary research interest is in the study and treatment of neuroblastoma. My clinical interests also include Wilms tumor, hepatoblastoma, post-transplant lymphoproliferative disorders, phase I therapies for hematologic malignancies, as well as palliative and end of life care.
As a clinical investigator in the Children's Oncology Group (COG), I am involved in the clinical trial design of treatment protocols for patients with neuroblastoma, and am the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium, a limited institution consortium which develops Phase I trials of novel therapies for patients with high risk and recurrent neuroblastoma. I am also interested in new therapies for the treatment of hematologic malignancies and am the Principal Investigator at Stanford for the Therapeutic Advances in Childhood Leukemia (TACL) Consortium, another limited institution consortium specifically dedicated to the development of novel therapies for relapsed leukemias.
Clinical Trials
- Not Recruiting Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
- Recruiting Study of MLN8237 in Combination With Irinotecan and Temozolomide
- Recruiting Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
- Recruiting Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
- Recruiting N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Publications
- Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Haematologica. 2012; (1): 30-7
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010; (3): 421-9
- Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010; (4): 648-54
- Detection of isolated tumor cells in neuroblastoma by immunohistochemical analysis in bone marrow biopsy specimens: improved detection with use of beta-catenin. Am J Clin Pathol. 2009; (1): 49-57
- 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma. Mol Imaging Biol. 2008 Jan-Feb; (1): 19-23
- Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008; (2): 381-3
Help